This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Influence of G-CSF and EPO on Associative Learning and Motor Skills

This study has been completed.
Information provided by:
University Hospital Muenster Identifier:
First received: March 1, 2006
Last updated: April 22, 2009
Last verified: April 2007
In the study we want to prove whether the subcutaneous application of granulocyte-stimulating factor (G-CSF) and erythropoetin (EPO) influence associative learning and/or motor skills of patients, who suffer from chronic stroke or amyotrophic lateral sclerosis. The study hypothesis is that G-CSF and EPO improve associative learning and/or motor skills.

Condition Intervention Phase
Chronic Stroke Amyotrophic Lateral Sclerosis Drug: granulocyte - colony stimulating factor (G-CSF) Drug: erythropoetin (EPO) Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Influence of G-CSF and EPO on Associative Learning and Motor Skills

Resource links provided by NLM:

Further study details as provided by University Hospital Muenster:

Primary Outcome Measures:
  • Learning success in a word learning model
  • Response time in motor function tests

Secondary Outcome Measures:
  • Response time in a word learning model
  • Total time and number of keystrokes in motor function tests

Estimated Enrollment: 180
Study Start Date: March 2006
Study Completion Date: March 2009
Primary Completion Date: March 2009 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Diagnosis of chronic stroke or amyotrophic lateral sclerosis

Exclusion Criteria:

  • leucocytes > 10000/µl
  • hematocrit > 48%
  • thrombocytes < 150000/µl
  • severe rheumatoid arthritis
  • severe infection
  • severe liver or renal failure
  • severe arterial hypertension
  • recurrent thromboembolic events
  • severe coronary heart disease
  • myocardial infarction
  • malignant tumor
  • leukemia
  • peripheral arterial occlusion disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00298597

Department of neurology, University Hospital of Muenster
Muenster, Nordrhein-Westfalen, Germany, D-48149
Sponsors and Collaborators
University Hospital Muenster
Principal Investigator: Wolf Rüdiger Schäbitz, MD Department of Neurology, University Hospital of Muenster, Germany
  More Information

Publications automatically indexed to this study by Identifier (NCT Number): Identifier: NCT00298597     History of Changes
Other Study ID Numbers: GCSFEPO_01
EudraCT Number 2005-001113-18
Study First Received: March 1, 2006
Last Updated: April 22, 2009

Additional relevant MeSH terms:
Motor Neuron Disease
Amyotrophic Lateral Sclerosis
Neurodegenerative Diseases
Nervous System Diseases
Neuromuscular Diseases
Spinal Cord Diseases
Central Nervous System Diseases
TDP-43 Proteinopathies
Proteostasis Deficiencies
Metabolic Diseases
Epoetin Alfa
Hematinics processed this record on July 19, 2017